Literature DB >> 25400027

Olfactomedin-4 is a candidate biomarker of solid gastric, colorectal, pancreatic, head and neck, and prostate cancers.

Catherine Guette1, Isabelle Valo, Alexandra Vétillard, Olivier Coqueret.   

Abstract

Olfactomedin-4 (OLFM4, OLM4) is a 72 kDa secreted glycoprotein belonging to the olfactomedin family. The OLFM4 gene expression is regulated by the transcription factors NF-kappa B and AP-1, and the OLM4 functions are poorly understood. OLM4 has been described as being able to interact with cell surface proteins such as lectins and concanavalin-A suggesting that one function of OLM4 is to regulate cell adhesion and migration. OLM4 is a marker for intestinal stem cells and is expressed at the bottom of the intestinal crypts. Expression of OLM4 during tumor development showed that OLM4 expression is increased in the early stages of tumor initiation. As OLM4 is a secreted protein, it is a prime candidate for biomarker research for tumor detection or progression. Levels of circulating OLM4 were significantly higher in patients with gastric, colorectal, and pancreatic cancers than in healthy subjects.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Biomarker; Cancer; OLFM4; Olfactomedin 4

Mesh:

Substances:

Year:  2014        PMID: 25400027     DOI: 10.1002/prca.201400083

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  9 in total

Review 1.  Diagnosis Biomarkers of Cholangiocarcinoma in Human Bile: An Evidence-Based Study.

Authors:  Fang Bao; Jiayue Liu; Haiyang Chen; Lu Miao; Zhaochao Xu; Guixin Zhang
Journal:  Cancers (Basel)       Date:  2022-08-13       Impact factor: 6.575

2.  Retinoid Chemoprevention: Who Can Benefit?

Authors:  Rodica P Bunaciu; Andrew Yen
Journal:  Curr Pharmacol Rep       Date:  2015-04-15

3.  The olfactomedin-4 positive neutrophil has a role in murine intestinal ischemia/reperfusion injury.

Authors:  Nick C Levinsky; Jaya Mallela; Amy M Opoka; Kelli Harmon; Hannah V Lewis; Basilia Zingarelli; Hector R Wong; Matthew N Alder
Journal:  FASEB J       Date:  2019-10-08       Impact factor: 5.834

Review 4.  Neutrophil phenotypes in health and disease.

Authors:  Pien Hellebrekers; Nienke Vrisekoop; Leo Koenderman
Journal:  Eur J Clin Invest       Date:  2018-05-25       Impact factor: 4.686

5.  High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer.

Authors:  Ryotaro Ohkuma; Erica Yada; Shumpei Ishikawa; Daisuke Komura; Hidenobu Ishizaki; Koji Tamada; Yutaro Kubota; Kazuyuki Hamada; Hiroo Ishida; Yuya Hirasawa; Hirotsugu Ariizumi; Etsuko Satoh; Midori Shida; Makoto Watanabe; Rie Onoue; Kiyohiro Ando; Junji Tsurutani; Kiyoshi Yoshimura; Takehiko Yokobori; Tetsuro Sasada; Takeshi Aoki; Masahiko Murakami; Tomoko Norose; Nobuyuki Ohike; Masafumi Takimoto; Masahiko Izumizaki; Shinichi Kobayashi; Takuya Tsunoda; Satoshi Wada
Journal:  PLoS One       Date:  2020-01-10       Impact factor: 3.240

6.  Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC.

Authors:  Yulong Wei; Qingzhu Song; Fenglan Zhang; Tian Yuan
Journal:  Can J Gastroenterol Hepatol       Date:  2021-12-06

7.  Qinbaohong Zhike Oral Liquid Attenuates LPS-Induced Acute Lung Injury in Immature Rats by Inhibiting OLFM4.

Authors:  Fangbo Zhang; Yu Li; Yujie Xi; Yi Zhang; Lifang Wang; He Xu; Jixiang Tian; FeiFei Guo; Hongjun Yang
Journal:  Oxid Med Cell Longev       Date:  2022-08-16       Impact factor: 7.310

8.  The alterations in the extracellular matrix composition guide the repair of damaged liver tissue.

Authors:  Mariliis Klaas; Triin Kangur; Janeli Viil; Kristina Mäemets-Allas; Ave Minajeva; Krista Vadi; Mikk Antsov; Natalia Lapidus; Martin Järvekülg; Viljar Jaks
Journal:  Sci Rep       Date:  2016-06-06       Impact factor: 4.379

Review 9.  Olfactomedin-4 in digestive diseases: A mini-review.

Authors:  Xin-Yu Wang; Sheng-Hui Chen; Ya-Nan Zhang; Cheng-Fu Xu
Journal:  World J Gastroenterol       Date:  2018-05-07       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.